S&R FARMACEUTICI SPA TOASTS TO A YEAR OF SUCCESS IN CARAPACE, BEVAGNA

With the foundation of S&R Farmaceutici Balcani and a turnover of 13 million 600 thousand euros, double compared to the last year, the company S&R Farmaceutici spa ended 2018 on a highly positive note and is ready to start 2019 from a vantage point thanks to its excellent track record, just three years since its foundation, in 2015.

The company based in Bastia Umbra was determined to share these results with its national sales network on occasion of the first cycle work meeting for 2019 which lasted four days and ended with dinner at the Carapace cellar at the Tenuta Castelbuono winery in Bevagna, on Wednesday 9th January. During the event, the Chief Executive Officer Mauro Dionigi officially presented plans for the building of new company headquarters in Bastia Umbra, with a total surface area of around 30 thousand square metres and an investment of over 20 million euros.

It will be inaugurated in 2021 and will contain a latest-generation pharmaceutical logistics and distribution hub, a congress hall with 300 seated places and a research & development centre for new products. 120 employees will operate at the facilities which together with professionals of the external sales network, will result in over 200 people working for S&R Farmaceutici.

The Chief Executive Officer Mauro Dionigi commented: “This past year has brought us great satisfaction. The latest is the recent foundation of S&R Farmaceutici Balcani, which shall target the foreign market of Albania first and foremost (it is based in Tirana) as well as the entire former Yugoslavia area. The operative structure consists of six staff members: a resident manager, a company sales manager, four medical-scientific representatives and an administrative assistant. S&R Farmaceutici Balcani is 70% owned by S&R Farmaceutici spa. The total investment amounts to around 500 thousand, including the purchase of shares held by the company’s previous owner, Italfarma, and for infrastructures required for operations”.

Dionigi added “Moreover, in 2018 the sale of products increased and new ones were acquired, further expanding our offering; we also strengthened partnerships with associations and institutions, in particular with the University of Perugia, as regards research in the fields of urology and gynaecology, our core business. Our hopes are high for 2019: our registered capital has increased from 1 to 2 million euros and has been fully paid up. Investor forecasts indicate the company will achieve a turnover of 22 million euros”.

The General Manager Lucio Leonardi is equally positive and adds: “In 2018 international agreements were signed with distributors from over 40 Countries in the world which, will enable us to achieve a turnover of over 8 million euros in the space of three years, on foreign markets alone”. Lastly, Leonardi also declared how “February will see the launch of a new line of medical-scientific information, ‘Primary Care’, in which 40 medical-scientific representatives will operate at a national level, spreading information about a new list of products acquired by S&R Farmaceutici. This line will further enrich the current uro-gynaecology line with 65 specialised representatives. This operation will enable S&R farmaceutici to reach out to it General Practitioners and specialist Physician targets.